Diving into Price-to-Book (P/B) Ratios for Health Stocks 💉
The P/B ratio compares a stock's market price to its book value—great for benchmarking against competitors or historical trends. And potentially can be used to find value stocks.
HOWEVER, a low P/B could mean it's undervalued... or just a dud. Always dig deeper!
I crunched numbers via Finchat on some health giants I've been eyeing. Here's the scoop:
- Eli Lilly (LLY): Sky-high P/B of 48.9—trading at a massive premium. But I like their Tirzepatide Zepbound product. Tons of profit potential from obesity.
- Novo Nordisk (NVO): P/B of 14.

My analysis on UnitedHealth $UNH was picked by the @tradingview team. 😇
It's mostly about fundamental analysis, and there are some great opportunities in the health sector. I'm also looking at $PFE, $LLY and $NVO

"The Little Book of Valuation" by Aswath Damodaran
The valuation professor's cheat sheet. Damodaran breaks down DCF, P/E ratios, and company valuation into bite-sized lessons. Perfect for understanding what companies are REALLY worth.
Amazon: 4.4 ⭐ | My rating: 4.0 ⭐

Introducing: My Monte Carlo Simulator with Kelly Criterion for Optimal Leverage!
I love this tool that I created and wanted to share with you all.
I've built a FREE tool that runs Monte Carlo simulations to find it! It calculates Kelly leverage, fractional Kelly, and optimal leverage based on historical data and thousands of sims.
Stress-test your setups, uncover tail risks, and optimize like a pro. 😎
Quick How-To:
- Select asset & historical data on the left.
- Set investment params (e.g., leverage: manual, full Kelly, fractional, or optimized).
- Choose sim method: Monte Carlo, GARCH, Marko